Hot API Axitinib CAS 319460-85-0
Axitinib is a multi-target small molecule inhibitor, the main targets are VEGFR, Kit, PDGFR, RET. The current approved INDICATION IS second-LINE THERAPY for advanced renal CANCER, which means THAT axitiniB is an option FOR advanced renal CANCER after SUTENT has failed. In addition to renal cancer, this drug has also been tried in patients with liver cancer, sarcoma, neuroendocrine tumors and other recognized antiangiogenic drugs are more sensitive to solid tumors, tumor blood supply is rich, also has a certain effect.
Overview
Hot API Axitinib CAS 319460-85-0 is a chemical with a molecular formula of C22H18N4OS and a molecular weight of 386.47000. Axitinib is suitable for the treatment of advanced renal cell disease and can also be used as an anti-tumor drug. The starting dose of axitinib is 5 mg per day, administered orally in two divided doses, and the dose can be adjusted according to the patient's tolerance. Axitinib can be taken with a meal or on an empty stomach, and should be taken approximately 12 hours apart. Generally, the adverse reactions are dysphonia, diarrhea, vomiting, fatigue, decreased appetite, weight loss and constipation. After adverse reactions, please consult your doctor for follow-up treatment.
Details
Name: Hot API Axitinib CAS 319460-85-0
EINECS:638-771-6
